Lille (France), Cambridge (Massachusetts, United States), February 9, 2012 – GENFIT (Alternext: ALGFT; ISIN:
FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing
on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces
its participation at the 14th annual Bio CEO Conference in New York on February 13-14, 2012.
During this conference, dedicated to publicly traded biotechnology companies, Jean-François Mouney, CEO of
GENFIT, will outline the Company’s perspectives to specialized analysts, and will notably present the latest
results of toxicology studies and clinical trials obtained for GFT505 in NAFLD/NASH.
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in
therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia,
inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive
solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in
partnership with leading pharmaceutical companies (SANOFI, SERVIER, …), to address these major public health
concerns and their unmet medical needs.
GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates
at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees.
GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN:
Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000
MILESTONES – Press Relations
Ph. +33 1 7544 8740 / +336 8788 4726 – email@example.com